A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis - -

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2009
This article has no abstract
Epistemonikos ID: 00e93ccaefc60afd4c0f94be210e792bcb6acf5c
First added on: Apr 17, 2025